Medtronic (MDT Quick QuoteMDT - Free Report) reported $9.76 billion in revenue for the quarter ended July 2026, representing a year-over-year increase of 13.7%. EPS of $1.45 for the same period compares to $1.26 a year ago.

The reported revenue represents a surprise of +3.02% over the Zacks Consensus Estimate of $9.47 billion. With the consensus EPS estimate being $1.39, the EPS surprise was +4.32%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Medtronic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- U.S. Revenue: $4.91 billion compared to the $4.82 billion average estimate based on two analysts. The reported number represents a change of +16.2% year over year.
• Net Sales- International: $4.85 billion compared to the $4.69 billion average estimate based on two analysts.
• Net Sales- World Wide Revenue: $9.76 billion versus the four-analyst average estimate of $9.53 billion.
• Net Sales- World Wide Revenue- Neuroscience: $2.68 billion versus $2.67 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.
• Net Sales- World Wide Revenue- Cardiovascular: $3.93 billion compared to the $3.78 billion average estimate based on four analysts. The reported number represents a change of +19.5% year over year.
• Net Sales- World Wide Revenue- Other: $29 million compared to the $19.75 million average estimate based on four analysts. The reported number represents a change of -59.7% year over year.
• Net Sales- World Wide Revenue- Medical Surgical- Surgical & Endoscopy: $1.74 billion versus the three-analyst average estimate of $1.72 billion. The reported number represents a year-over-year change of +7.9%.
• Net Sales- World Wide Revenue- Medical Surgical: $2.28 billion compared to the $2.24 billion average estimate based on three analysts. The reported number represents a change of +9.4% year over year.
• Net Sales- World Wide Revenue- Neuroscience- Neuromodulation: $539 million versus $567.41 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.9% change.
• Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies: $1.37 billion versus $1.34 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.
• Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies: $774 million versus $769.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.3% change.
• Net Sales- World Wide Revenue- Diabetes: $843 million versus the three-analyst average estimate of $829.71 million. The reported number represents a year-over-year change of +16.9%.

View all Key Company Metrics for Medtronic here>>>

Shares of Medtronic have returned +4.6% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.